LeMaitre Vascular/$LMAT
1D1W1MYTD1Y5YMAX
Capital at risk
About LeMaitre Vascular
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
- Ticker
- $LMAT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 651
- Headquarters
- Burlington, United States
- Website
- www.lemaitre.com
LMAT Metrics
BasicAdvanced
$1.8B
28.13
$2.86
0.52
$0.95
1.24%
Price and volume
Market cap
$1.8B
Beta
0.52
52-week high
$118.01
52-week low
$78.27
Average daily volume
391K
Dividend rate
$0.95
Financial strength
Current ratio
16.312
Quick ratio
13.761
Long term debt to equity
0.444
Total debt to equity
0.453
Dividend payout ratio (TTM)
31.21%
Interest coverage (TTM)
13.95%
Profitability
EBITDA (TTM)
83.021
Gross margin (TTM)
71.87%
Net profit margin (TTM)
25.02%
Operating margin (TTM)
27.63%
Effective tax rate (TTM)
22.50%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
7.44%
Return on equity (TTM)
16.77%
Valuation
Price to earnings (TTM)
28.13
Price to revenue (TTM)
6.97
Price to book
4.37
Price to tangible book (TTM)
5.68
Price to free cash flow (TTM)
24.778
Free cash flow yield (TTM)
4.04%
Free cash flow per share (TTM)
3.244
Dividend yield (TTM)
1.18%
Forward dividend yield
1.24%
Growth
Revenue change (TTM)
11.85%
Earnings per share change (TTM)
39.46%
3-year revenue growth (CAGR)
13.99%
10-year revenue growth (CAGR)
12.37%
3-year earnings per share growth (CAGR)
36.23%
10-year earnings per share growth (CAGR)
19.08%
3-year dividend per share growth (CAGR)
19.30%
10-year dividend per share growth (CAGR)
18.14%
What the Analysts think about LMAT
Analyst ratings (Buy, Hold, Sell) for LeMaitre Vascular stock.
Analyst projections of the future price of LeMaitre Vascular stock.
Bulls say / Bears say
LeMaitre’s Q1 2026 results showed net sales of $66.6 million (+11% y/y; +10% organic), gross margin expansion of 350 bps to 72.7%, operating income up 41% to $17.8 million, and EPS of $0.68 (+42%), driving a full-year sales guidance raise to $280 million (+12%) and adjusted EPS growth of 26% (SEC 8-K).
The Artegraft bovine graft product grew 36% worldwide in Q1 2026, underscoring the strength and rapid adoption of LeMaitre’s differentiated biologics portfolio (SEC 8-K).
In Q2 2026, net sales of $70.4 million (+10% y/y) missed the IBES estimate of $71 million, and LeMaitre cut its full-year revenue guidance midpoint to $276.3 million (11% growth) from $280 million (12%), reflecting execution risk and macro headwinds (SEC 10-Q; MarketBeat).
Cardiac allograft sales were hampered by supply constraints—cited as one of three primary reasons for the Q2 2026 sales shortfall—highlighting vulnerability in a key growth driver (Investing.com).
LeMaitre has completed no material acquisitions since 2020, and its 2025 annual report warns of a limited pipeline of viable M&A targets—which may constrain scale, diversification, and long-term growth prospects (LeMaitre 2025 Annual Report).
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2026.
LMAT Financial Performance
Revenues and expenses
LMAT Earnings Performance
Company profitability
Upcoming events
No upcoming events
LMAT News
AllArticlesVideos
Funds containing LMAT
AllUSDGBPEUR
Fund name | Fund size | $LMAT weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.10% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.10% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.06% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.